BackDuopharma Biotech Berhad Overview

Duopharma Biotech Berhad Receivables

Duopharma Biotech Berhad's receivables is $280M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$282.80M
↑ 18.41% YoYΔ $43.97M vs prior year quarter

Peer trimmed avg / median

Loading

Duopharma Biotech Berhad Receivables History

Loading

Duopharma Biotech Berhad vs. peers: Receivables Comparison

Loading

Duopharma Biotech Berhad Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Duopharma Biotech Berhad (7148.KL) FAQ

Duopharma Biotech Berhad posts a receivables of $280M as of June 2026. That compares with $240M in the prior-year period — up 18.4% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Duopharma Biotech Berhad's receivables was $240M. The latest reading is $280M — a 18.4% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of Duopharma Biotech Berhad's financial statement story. At $280M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for 7148.KL's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Duopharma Biotech Berhad's other metric pages and overview cover the third.